Bioventix PLC (LON:BVXP - Get Free Report)'s share price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of GBX 2,625.17 ($35.52) and traded as high as GBX 2,950 ($39.92). Bioventix shares last traded at GBX 2,895.79 ($39.19), with a volume of 27,208 shares.
Bioventix Price Performance
The company has a 50 day moving average of GBX 2,628.80 and a 200-day moving average of GBX 3,034.45. The company has a market capitalization of £149.24 million, a P/E ratio of 18.43 and a beta of 0.35.
Bioventix (LON:BVXP - Get Free Report) last issued its quarterly earnings results on Monday, March 31st. The biotechnology company reported GBX 72.27 ($0.98) earnings per share for the quarter. Bioventix had a net margin of 59.51% and a return on equity of 69.09%. Research analysts predict that Bioventix PLC will post 166.3066955 EPS for the current fiscal year.
Bioventix Cuts Dividend
The business also recently announced a dividend, which was paid on Friday, April 25th. Investors of record on Thursday, April 10th were given a dividend of GBX 70 ($0.95) per share. The ex-dividend date was Thursday, April 10th. This represents a yield of 2.95%. Bioventix's dividend payout ratio (DPR) is presently 102.19%.
Insider Buying and Selling at Bioventix
In other news, insider Bruce Hiscock bought 31 shares of the firm's stock in a transaction on Monday, April 28th. The shares were bought at an average price of GBX 2,632 ($35.62) per share, for a total transaction of £815.92 ($1,104.09). 8.02% of the stock is currently owned by corporate insiders.
About Bioventix
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
Featured Articles
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
